Screener
Gyre Therapeutics, Inc. GYRE Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed August 7, 2026. Open the filing →
- Filed
- Aug 7, 2026, 5:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-340448
FAQ
- What is Gyre Therapeutics, Inc.'s retained earnings?
- Gyre Therapeutics, Inc. (GYRE) reported retained earnings of -$137.96M in Q2 2026.
- How has Gyre Therapeutics, Inc.'s retained earnings changed year-over-year?
- Gyre Therapeutics, Inc.'s retained earnings decreased by 96.2% year-over-year, from -$70.31M to -$137.96M.
- What is the long-term trend for Gyre Therapeutics, Inc.'s retained earnings?
- Over 5 years (2020 to 2025), Gyre Therapeutics, Inc.'s retained earnings has grown at a -18.6% compound annual growth rate (CAGR), from -$314.76M to -$112.6M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about Gyre Therapeutics, Inc.'s retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude